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OBJECTIVE: Endostatin is a potent endogenous inhibitor of angiogenesis. It is derived from the proteolytic cleavage
of collagen XVIII, which is encoded by the COL18A1 gene. A polymorphic COL18A1 allele encoding the functional
polymorphism p.D104N impairs the activity of endostatin, resulting in a decreased ability to inhibit angiogenesis.
This polymorphism has been previously analyzed in many types of cancer and has been considered a phenotype
modulator in some benign and malignant tumors. However, these data are controversial, and different results have
been reported for the same tumor types, such as prostate and breast cancer. The purpose of this study was to
genotype the p.D104N variant in a cohort of pediatric and adult patients with adrenocortical tumors and to
determine its possible association with the biological behavior of adrenocortical tumors.
METHODS: DNA samples were obtained from 38 pediatric and 56 adult patients (0.6–75 yrs) with adrenocortical
tumors. The DNA samples were obtained from peripheral blood, frozen tissue or paraffin-embedded tumor blocks
when blood samples or fresh frozen tissue samples were unavailable. Restriction fragment length polymorphism
analysis was used to genotype the patients and 150 controls. The potential associations of the p.D104N
polymorphism with clinical and histopathological features and oncologic outcome (age of onset, tumor size,
malignant tumor behavior, and clinical syndrome) were analyzed.
RESULTS: Both the patient group and the control group were in Hardy–Weinberg equilibrium. The frequencies of
the p.D104N polymorphism in the patient group were 81.9% (DD), 15.9% (DN) and 2.2% (NN). In the controls, these
frequencies were 80.6%, 17.3% and 2.0%, respectively. We did not observe any association of this variant with
clinical or histopathological features or oncologic outcome in our cohort of pediatric and adult patients with
adrenocortical tumors.
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INTRODUCTION
Collagen XVIII/endostatin is a heparan sulfate proteo-
glycan component of nearly all epithelial and endothelial
basement membranes (1). The gene COL18A1 is located on
chromosome 21 at 21q22.3 and contains 10 collagenous
domains that are interrupted and flanked by non-
collagenous domains (2). A proteolytic fragment produced
by the cleavage of the C-terminal non-collagenous domain
(NC1) is known as endostatin and has been shown to
exhibit anti-angiogenic activity in vitro and in vivo (3). As
an angiogenic inhibitor, endostatin prevents tumor growth
and expansion by controlling the formation of new blood
vessels (4). The observation that individuals with trisomy
21 (Down’s syndrome) rarely develop solid tumors
suggests the presence of an endogenous angiogenesis
inhibitor encoded by a gene on chromosome 21 (5). A
single nucleotide polymorphism c.4309G.A( p . D 1 0 4 N )
was identified in the endostatin domain of COL18A1 (6).
Lughetti et al. reported that, relative to control individuals,
patients who are heterozygous for this polymorphism
(DN) had a 2.5-fold greater chance of developing solid
tumors, such as prostate cancer (7). This finding likely
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95indicates that this polymorphism results in a less active
protein and that individuals who carry one or more
m u t a n ta l l e l e sa tt h i sl o c u sa r em o r ep r o n et od e v e l o p i n g
aggressive prostate cancer (7). In contrast, Macpherson et
al. observed no significant difference in the normal
homozygous (DD), heterozygous (DN), and mutant homo-
zygous (NN) frequencies between androgen-independent
prostate cancer patients and control individuals (8).
During embryonic development and postnatal growth
and repair, angiogenesis or neovascularization from the
preexisting vasculature is crucial (9). The formation of new
blood vessels is a complex multistage process that involves
the proteolytic degradation of the basement membrane, the
loss of endothelial cells into the surrounding stroma, and
finally, the re-adhesion of endothelial cells to form new
capillary tubes (9). The growth of tumors is associated with
increased angiogenesis, during which the formation of new
blood vessels is a fundamental step in tumor development
and expansion. In addition, neovascularization is a critical
component of tumor metastasis and disease progression
(10). This connection between angiogenesis and tumor
progression has been documented in clinical studies, which
have demonstrated a correlation between unbalanced
angiogenic factors and metastatic tumors with poor survival
rates (11). The normal (i.e., non-tumorous) adrenal gland is
a highly vascularized tissue that is centripetally irrigated by
a network of fenestrated capillaries (12). Whereas adreno-
cortical tumors and the normal adrenal cortex have a similar
vascular pattern (13), adrenocortical carcinomas display a
disorganized vasculature, with large vessels interspersed
with irregular networks of microcapillaries (13). As endo-
statin is involved in angiogenesis, we hypothesized that the
presence of the D104N polymorphism may influence the
outcome of adrenocortical cancer.
OBJECTIVE
The aim of this study was to analyze the frequency of the
DD (normal homozygous), DN (heterozygous), and NN
(mutant homozygous) genotypes of the p.D104N poly-
morphism in patients with adrenocortical tumors and to
identify any associations with clinical and biological
features. The cohort consisted of pediatric and adult
patients with adrenocortical tumors (benign and malignant)
who were seen at the Hospital das Clı ´nicas, University of
Sa ˜o Paulo, Brazil, from 1990 to 2010.
PATIENTS AND METHODS
Subjects
DNA samples were obtained from different tissues
depending on the viability of the samples. Peripheral blood
(n=17), fresh frozen tissue (n=70), and paraffin embedded
tissue samples (n=7) were collected from 94 patients with
adrenocortical tumors. Thirty-eight patients were pediatric
(1 to 17 yrs of age; 10 carcinomas, 7 with a poor outcome),
and fifty-six were adults (18 to 70 yrs of age; 25 carcinomas,
17 with a poor outcome).
The clinical data are presented in Table 1. All of the cases
were diagnosed between 1990 and 2010. In addition, 300
alleles from 150 healthy volunteers were analyzed to
determine the frequency of the D104N endostatin poly-
morphism.
DNA amplification and restricted fragment length
polymorphism analysis
A fragment from exon 42 of the COL18A1 gene was
amplified using PCR with the following primers: 59-ACA
AAC ACC CAC ACC CAT C-39 and 59-GGG CTC CTA TCT
GCA GTT TC-39. For paraffin-embedded tumor blocks, the
following primers were used: 59-GCT GGG AGG CTC TGT
TCT CAG-39 59-TAG GTT CCC AGT GCC GTG TGA-39.
When the DNA was obtained from fresh tissue or
leukocytes, we were able to amplify a 261 bp fragment,
but when the DNA was obtained from paraffin-embedded
tumor blocks, new primers were designed to amplify a
119 bp fragment. PCR amplification was performed using a
previously described protocol (14).
Both of the fragments (261 and 119 bp) were subjected to
RFLP analysis using the restriction enzyme MseI, and the
fragments were separated by electrophoresis in a 2.0%
agarose gel.
The 261 and 119 bp fragments were subjected to RFLP
analysis using the restriction enzyme MseI, and the
fragments were separated by electrophoresis in a 2.0%
agarose gel (Figure 1).
Table 1 - Clinical data from 94 patients with
adrenocortical tumors.
Characteristic Pediatric group Adult group
Number of patients 38 56
Median age in years (range) 2.5 (0.8–18) 35.28 (18–74.8)
Gender 10M/28F 6M/50F
Hormone-secreting tumors 38 47
Tumor size (cm) 5.6 (1.5–20) 4.5 (2–20)
Weiss score
0–2 12 29
3–5 15 14
6–9 11 13
MacFarlane stage
I–II 32 34
III–IV 6 22
Specific death 7 16
Time to death, months (range) 13.7 (7–16) 13.6 (8–35.4)
Follow-up, months (range) 66 (1–167) 44.6 (1–203)
*A Weiss score $3 and a MacFarlane stage $III were considered
adrenocortical carcinoma in the pediatric group. A Weiss score $3 was
considered adrenocortical carcinoma in the adult group.
Figure 1 - Electrophoresis of PCR and RFLP – The lines 2, 4 and 5
indicate the heterozygous pattern. The line 8 represents the
homozygous pattern and the M corresponds to the molecular
weight marker Øx.
COL18A1 polymorphism and adrenocortical tumors
Mariani BMP et al.
CLINICS 2012;67(2):95-98
96Statistical analyses
Descriptive analyses were performed to determine the
frequencies and distributions of the demographic variables.
The genotype frequencies in the adrenocortical tumor
patients and control individuals were compared using
contingency table analyses and the chi-square or Fisher’s
exact test, when necessary. The odds ratio and the
corresponding confidence intervals were estimated using
standard methods. Statistical analyses were performed
using STATA 9.0 statistical software. The Hardy–Weinberg
equilibrium was tested with the chi-square test to determine
the goodness-to-fit (one degree of freedom).
RESULTS
The frequencies of the alleles in both the patients and
controls were in Hardy–Weinberg equilibrium.
Of the 94 patients, 15 were heterozygous for the p.D104N
polymorphism (DN), and 2 were homozygous for the
p.D104N polymorphism (NN). Of the 150 controls, 26 were
heterozygous for the p.D104N polymorphism, and 3 were
homozygous for the mutant allele. The genotype frequency
of this polymorphism did not differ between the patients
(17%) and controls (19%) (p=0.82).
Of the 17 patients carrying the mutant allele, 14 were
adults; 8 of these adult patients were diagnosed with
adenoma, and 6 were diagnosed with carcinoma. All of these
patients were heterozygous (DN) for the polymorphism
(p=0.50). The three remaining patients carrying the mutant
allele were pediatric patients, and all were diagnosed with a
benign adrenocortical tumor. Two of these pediatric patients
were homozygous (NN) for the mutant allele, and one was
heterozygous (DN) (p=0.38). No statistical difference was
observed among the genotypes frequencies (DD, DN, and
NN) in this cohort with respect to the clinical data, including
the presence of Cushing’s syndrome (p=0.76), the presence
of virilization (p=0.07), tumor weight or size (p=0.35), Weiss
score (p=0.3), metastasis occurrence (p=0.43), disease
recurrence (p=0.51), and patient mortality (p=0.8).
DISCUSSION
Following the observation that individuals with trisomy
21 (Down’s syndrome) rarely develop solid tumors,
Folkman and Kalluri proposed that an endogenous angio-
genesis inhibitor is likely encoded by a gene on chromo-
some 21 (5). Endostatin was first isolated from the
conditioned media of a non-metastatic murine hemangioen-
dothelioma cell line, EOMA. EOMA cell–conditioned media
inhibited the proliferation of FGF-2-stimulated bovine
capillary endothelial cells (15).
Preclinical experiments in which endostatin is exogen-
ously administered to cancer patients have been used to
evaluate its anti-tumor activity and to determine whether its
endogenous anti-angiogenic effect controls the formation of
new blood vessels, which is a necessary event for tumor
metastasis (16).
A non-synonymous polymorphism (p.D104N) in exon 42
of COL18A1, which encodes endostatin, was described by
Yugetti et al. The presence of this mutation leads to
decreased activity of the protein, which may 1) interfere
with the anti-angiogenic role of endostatin and 2) be
associated with the progression of solid tumors, such as
breast cancer and prostate cancer (7,17). This particular
polymorphism has also been evaluated in other types of
cancers, such as leukemia (18). However, there have been
contradictory reports regarding the association between this
polymorphism and prostate tumors and breast tumors
when analyzed in different cohorts (7,18).
Adrenocortical tumors are highly vascularized tumors;
we therefore hypothesized that a functional polymorphism
located in the endostatin-coding region of COL18A1 may be
associated with the poor behavior of the tumors, leading to
early metastasis and death.
In the present study, we identified no association
between the p.D104N endostatin polymorphism and
tumor aggressiveness or other clinical features in pediatric
and adult patients. The lack of an association observed
in our adrenocortical cancer population has also been
observed in other tumors types. Similar studies of patients
with leukemia and multiple myeloma revealed no associa-
tion between the endostatin p.D104N polymorphism and
disease outcome (18,19). The discrepancy between these
results may be due to the limited size of the studied
population. For example, studies performed by Iughetti et
al. and Lourenc ¸o et al. (20) revealed a high risk of sporadic
breast cancer in individuals homozygous (NN) for the
p.D104N polymorphism. However, these studies exam-
ined a small number of patients, and the allelic frequencies
were not in Hardy–Weinberg equilibrium (X
2=22.87,
p,0.001). Alternatively the different results could also be
due to disease heterogeneity. Other candidate genes
should be investigated with respect to their involvement
in angiogenesis.
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